...
SLXNWMICRO

Silexion Therapeutics Ltd.

HealthcareBiotechnology
$0.03
$0.00(-8.99%)
52W$0.02
$0.09
FinancialsValuationvs ALNY
Updated Mar 2, 12:00 AM
RSI52
RS Rating34/99
Beta1.29
Volatility211%
F-Score2/9
Mkt Cap$64M
DOWNTREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

DOWNTREND

Silexion Therapeutics Ltd. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is weak (RS Rating: 34), showing significant lag compared to the market leaders. Earnings growth of 116% provides fundamental context to the price action. Investors should exercise caution due to high volatility (211% annualized), which requires wider risk management.

Relative Strength
34
out of 99
Lagging
Trend Score
0/4
Minervini Criteria
DOWNTREND
Risk (Beta)
1.29
vs S&P 500
ABOVE MKT
52W Position
21%
from 52W low
Lower Half
Trend & Momentum Analysis

Trend Template (Minervini)

DOWNTREND0/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$0.04
50 SMA > 100 SMA$0.04
100 SMA > 150 SMA$0.04
150 SMA > 200 SMA$0.04

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$0.04-4.97%BELOW
50 SMA$0.04-1.99%BELOW
100 SMA$0.04-3.37%BELOW
150 SMA$0.04-9.47%BELOW
200 SMA$0.04-18.29%BELOW

Price Performance

1D-9.0%
1W-9.0%
1M-12.2%
3M+14.3%
6M+1.8%
YTD+32.3%
1Y-42.7%
3Y-41.3%
52-Week Trading Range21% from low
$0.03
52W Low$0.02
52W High$0.09

Technical Indicators

RSI (14)NEUTRAL
52.3
305070
VCP ScoreCOOL
5/10
Base depth: 87.2%

Risk Profile

Beta
1.29
52W Vol
211%
ATR
$0.01
Max DD (1Y)
-69%

Volume Analysis

Today
—
50D Avg
48.9K
Vol Ratio
0.00x
Liquidity
ILLIQUID

Earnings Momentum

Q4'24-303%
$-2.70
Q1'25+155%
$0.26
Q2'25-1562%
$-4.32
Q3'25+116%
$2.88
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:—
5 Years:—
3 Years:—
TTM:—

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+80.31%

Stock Price CAGR

10 Years:-14.77%
5 Years:-27.35%
3 Years:-41.29%
1 Year:-42.67%

Return on Equity

10Y Avg:-0.1%
5Y Avg:-0.1%
3Y Avg:1.1%
Last Year:-132.5%

Key Metrics

Market Cap$64M
Gross Margin—
Net Margin—
Piotroski F-Score2/9

More SLXNW Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

SLXNW vs ALNYALNYIONSARWRCRSP

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 34 meansSLXNW outperformed 34% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.29 means 29% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 2/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 5/10 with COOL status.

Frequently Asked Questions

Is SLXNW in an uptrend right now?

SLXNW has a trend score of 0/4 based on Minervini's Stage Analysis. Currently showing broken structure - 0 of 4 trend criteria are met.

Is SLXNW overbought or oversold?

SLXNW's RSI (14) is 52. The stock is in neutral territory, neither overbought nor oversold.

Is SLXNW outperforming the market?

SLXNW has a Relative Strength (RS) Rating of 34 out of 99. SLXNW is currently lagging the broader market.

Where is SLXNW in its 52-week range?

SLXNW is trading at $0.03, which is 38% of its 52-week high ($0.09) and 21% above its 52-week low ($0.02).

How volatile is SLXNW?

SLXNW has a Beta of 1.29 and 52-week volatility of 211%. It's more volatile than the S&P 500 - expect bigger swings.